For a drug to work, the molecule must bind to its target. That’s tricky for elusive targets lacking typical binding sites, but that hurdle can be overcome with molecular glue, a molecule that brings ...

About one-third of all drugs approved by the Food and Drug Administration target the largest family of cell membrane receptors called G protein-coupled receptors (GPCRs). GPCRs are indispensable for ...

Google DeepMind has unexpectedly released the source code and model weights of AlphaFold 3 for academic use, marking a significant advance that could accelerate scientific discovery and drug ...

Researchers from the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which now predicts molecular binding ...

(L to R) Co-first authors Sarah Young, PhD, St. Jude Department of Chemical Biology and Therapeutics, Lauren Mascibroda, PhD, St. Jude Department of Pathology, and Gisele Nishiguchi, St. Jude ...

A recent study investigated whether a transglutaminase 2 inhibitor has potential as a drug to treat celiac disease. Previous tissue studies have shown that the ZED1227 transglutaminase 2 inhibitor ...

A Japanese research team has demonstrated that the use of antisense oligonucleotides (ASOs) with modified bases and sugars can enhance the effectiveness of targeting diseases in the central nervous ...

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a ...

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables the precise functionalization of peptides and proteins. This approach ...

(Nanowerk Spotlight) The precise delivery of cancer drugs to tumors has remained one of medicine's most difficult challenges. Traditional chemotherapy affects the entire body indiscriminately, while ...